Table 3 Risk factors for patients included in R2-ISS stages (pooled data from ICARIA-MM and IKEMA).
R2-ISS stage | ||||||
|---|---|---|---|---|---|---|
Stage I (n = 68) | Stage II (n = 136) | Stage III (n = 204) | Stage IV (n = 55) | Not classified (n = 146) | All (n = 609) | |
No risk factors present | 68 (100%) | 0 | 0 | 0 | 0 | 68 (11.2%) |
ISS stage II at study entry | 0 | 48 (35.3%) | 89 (43.6%) | 15 (27.3%) | 53 (36.3%) | 205 (33.7%) |
ISS stage III at study entry | 0 | 0 | 62 (30.4%) | 39 (70.9%) | 22 (15.1%) | 123 (20.2%) |
Lactate dehydrogenase >upper limit of normal | 0 | 19 (14.0%) | 58 (28.4%) | 47 (85.5%) | 42 (28.8%) | 166 (27.3%) |
del(17p)a present | 0 | 10 (7.4%) | 25 (12.3%) | 27 (49.1%) | 9 (6.2%) | 71 (11.7%) |
t(4;14)a present | 0 | 6 (4.4%) | 42 (20.6%) | 18 (32.7%) | 2 (1.4%) | 68 (11.2%) |
1q21+b present | 0 | 53 (39.0%) | 142 (69.6%) | 47 (85.5%) | 13 (8.9%) | 255 (41.9%) |
